PRevention Using EPA Against coloREctal Cancer

Summary

This research study is evaluating the effect of AMR101 as a possible chemopreventive agent to reduce risk of colorectal cancer in individuals with a history of colorectal adenoma. \- The name of the study drug involved in this study is: \-- AMR101 (VASCEPA).

Timeline

Start

2020-12-09

Primary completion

2022-09-30

Completion

2022-09-30

Publications

• Chen Y, Bae S, Wang K, Du M, Lu Y, Sun Q, Labelle PA, Caraballo A, Lachut K, Husain A, Hote L, Koehn M, Prezioso E, Reinicke T, Schuck M, Sethurathnam J, Solowey J, Woo J, Carolan PJ, Chung DC, Colizzo FP 3rd, Gala M, Khalili H, Nishioka NS, Richter JM, Staller K, Yarze JC, Ma W, Pratt D, Singh A, Nguyen LH, Jacobson BC, Luther J, Kuo B, Dougan M, Rosner B, Magicheva-Gupta M, Drew DA, Chan AT, Song M. Effect of icosapent ethyl treatment on colorectal tissue marine omega-3 polyunsaturated fatty acid levels among patients with a history of adenoma: a prospective, single-arm clinical trial. Am J Clin Nutr. 2026 Jun 25:101419. doi: 10.1016/j.ajcnut.2026.101419. Online ahead of print.

Drugs

Indications